Lyell Immunopharma (LYEL) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 75.5% versus a loss of 51.6%. Over five years, SLGL leads with a -22.8% price change compared with -96.8% for LYEL. Sol-Gel Technologies is the larger company by market cap ($230.5 million vs $214.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LYEL | SLGL |
|---|---|---|
| Share price | $8.74 | $70.40 |
| Market cap | $214.17M | $230.49M |
| 1-day change | +2.10% | -2.15% |
| YTD return | -72.19% | +70.73% |
| 1-year return | -51.61% | +75.52% |
| 5-year return | -96.78% | -22.85% |
| EPS (TTM) | $-12.86 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.00 | $97.97 |
| 52-week low | $8.21 | $28.81 |
| Distance from 52-week high | -80.58% | -28.14% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +333.41% | +116.62% |
| Average volume | 144.81K | 55.30K |
| Shares outstanding | 24.51M | 3.27M |
| Employees | 161 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed LYEL by 127.1 percentage points over the past year.
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
LYEL vs SLGL FAQ
Which is bigger, Lyell Immunopharma or Sol-Gel Technologies?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $230.49M compared with $214.17M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, LYEL or SLGL?
SLGL returned +75.52% over the past 12 months, compared with -51.61% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Lyell Immunopharma and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.